Combining both fusion partner and intragenic fusions, we identified a total of 10 RET+ CRC patients out of 14,812 CRC patients (0.07%), 109 RET+ NSCLC patients out of 21,397 NSCLC patients (0.5%), and 75 RET+ thyroid cancer patients out of 1944 non‐medullary thyroid cancer patients (3.9%). This evidence concerns the gene RET and thyroid gland carcinoma.